Barclays PLC Tango Therapeutics, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Tango Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 126,281 shares of TNGX stock, worth $391,471. This represents 0.0% of its overall portfolio holdings.

Number of Shares

126,281

Previous 126,281 -0.0%

Holding current value

$391,471

Previous $972,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$7.36 - $11.93 $408,259 - $661,757	55,470 Added 78.34%	126,281 $972,000
Q2 2024 Aug 14, 2024	SELL	$6.66 - $10.15 $750,415 - $1.14 Million	-112,675 Reduced 61.41%	70,811 $608,000
Q1 2024 May 15, 2024	SELL	$7.51 - $12.88 $138,281 - $237,159	-18,413 Reduced 9.12%	183,486 $1.46 Million
Q4 2023 Feb 15, 2024	BUY	$6.52 - $12.01 $743,390 - $1.37 Million	114,017 Added 129.74%	201,899 $2 Million
Q3 2023 Nov 07, 2023	BUY	$2.93 - $11.26 $92,640 - $356,018	31,618 Added 56.2%	87,882 $990,000
Q2 2023 Aug 03, 2023	SELL	$2.67 - $4.7 $8,717 - $15,345	-3,265 Reduced 5.48%	56,264 $187,000
Q1 2023 May 04, 2023	SELL	$3.76 - $8.06 $86,453 - $185,323	-22,993 Reduced 27.86%	59,529 $235,000
Q4 2022 Feb 13, 2023	SELL	$3.41 - $8.29 $126,828 - $308,329	-37,193 Reduced 31.07%	82,522 $599,000
Q3 2022 Nov 03, 2022	SELL	$3.25 - $5.46 $62,143 - $104,400	-19,121 Reduced 13.77%	119,715 $433,000
Q2 2022 Aug 12, 2022	BUY	$3.86 - $8.01 $61,478 - $127,575	15,927 Added 12.96%	138,836 $629,000
Q1 2022 May 16, 2022	BUY	$7.01 - $10.94 $861,592 - $1.34 Million	122,909 New	122,909 $932,000

Others Institutions Holding TNGX

# of Institutions

123

Shares Held

91.7M

Call Options Held

3.1K

Put Options Held

1.5K

View Full List

About Tango Therapeutics, Inc.

Ticker TNGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 88,067,296
Market Cap $273M
Description
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops...

More about TNGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account